UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Monitoring patients treated with anti-TNF-α biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies

Rheumatology (Oxford, England), 2007-12, Vol.46 (12), p.1828-1834

2007

Volltextzugriff (PDF)

Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab?

Alimentary pharmacology & therapeutics, 2017-03, Vol.45 (5), p.759-760

2017

Volltextzugriff (PDF)

Monitoring patients treated with anti-TNF- biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies

Rheumatology (Oxford, England), 2007-12, Vol.46 (12), p.1828-1834

2007

Volltextzugriff (PDF)

Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2011-07, Vol.34 (1), p.51-58

2011

Volltextzugriff (PDF)

Prognostic laboratory markers of joint damage in rheumatoid arthritis

Annals of the rheumatic diseases, 2005-02, Vol.64 (2), p.196-201

2005

Volltextzugriff (PDF)

Lewis and AB0 blood group-phenotypes in periodontitis, cardiovascular disease, obesity and stroke

Scientific reports, 2019-04, Vol.9 (1), p.6283-6283, Article 6283

2019

Volltextzugriff (PDF)

Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis

Annals of the rheumatic diseases, 2009-11, Vol.68 (11), p.1739-1745

2009

Volltextzugriff (PDF)

Pre‐existing IgG antibodies cross‐reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2013-06, Vol.37 (12), p.1172-1183

2013

Volltextzugriff (PDF)

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

Neurology, 2005-07, Vol.65 (1), p.33-39

2005

Volltextzugriff (PDF)

Cytokines, autoantibodies and viral antibodies in premorbid and postdiagnostic sera from patients with rheumatoid arthritis: case–control study nested in a cohort of Norwegian blood donors

Annals of the rheumatic diseases, 2008-06, Vol.67 (6), p.860-866

2008

Volltextzugriff (PDF)

Letter: persistence of anti-infliximab antibodies after discontinuation of infliximab in patients with IBD

Alimentary pharmacology & therapeutics, 2012-09, Vol.36 (5), p.499-500

2012

Volltextzugriff (PDF)

Is there a need for immunopharmacologic guidance of anti–tumor necrosis factor therapies?

Arthritis & rheumatology (Hoboken, N.J.), 2011-04, Vol.63 (4), p.867-870

Bendtzen, Klaus

2011

Volltextzugriff (PDF)

Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease

Alimentary pharmacology & therapeutics, 2012-10, Vol.36 (7), p.650-659

2012

Volltextzugriff (PDF)

Single nucleotide polymorphisms in genes encoding toll-like receptors 7, 8 and 9 in Danish patients with systemic lupus erythematosus

Molecular biology reports, 2014-09, Vol.41 (9), p.5755-5763

2014

Volltextzugriff (PDF)

Serum concentrations of the interferon-γ-inducible chemokine IP-10/CXCl10 are augmented in both newly diagnosed Type I diabetes mellitus patients and subjects at risk of developing the disease

Diabetologia, 2002-08, Vol.45 (8), p.1107-1110

2002

Volltextzugriff (PDF)

Genetic polymorphisms of dsRNA ligating pattern recognition receptors TLR3, MDA5, and RIG-I. Association with systemic lupus erythematosus and clinical phenotypes

Rheumatology international, 2014-10, Vol.34 (10), p.1401-1408

2014

Volltextzugriff (PDF)

Neutralizing antibodies hamper IFNβ bioactivity and treatment effect on MRI in patients with MS

Neurology, 2006-11, Vol.67 (9), p.1681-1683

2006

Volltextzugriff (PDF)

Lower limb ischaemia and reperfusion injury in healthy volunteers measured by oxidative and inflammatory biomarkers

Perfusion, 2015-01, Vol.30 (1), p.64-70

2015

Volltextzugriff (PDF)

Specific and Strain-Independent Effects of Dexamethasone in the Prevention and Treatment of Experimental Autoimmune Encephalomyelitis in Rodents

Scandinavian journal of immunology, 2010-11, Vol.72 (5), p.396-407

2010

Volltextzugriff (PDF)

FRI0031 Naturally occurring antibodies against different IFN-alpha subtypes are observed in some SLE patients, and may impact the IFN gene signature and disease activity

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.320-320

2013

Volltextzugriff (PDF)

Commentary: antibodies reacting with the infliximab Fab portion – something new? Authors' reply

Alimentary pharmacology & therapeutics, 2013-09, Vol.38 (5), p.552-553

2013

Volltextzugriff (PDF)

Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor‐α and interferon‐γ, and has potential in the treatment of arthritis

Clinical and experimental immunology, 2003-10, Vol.134 (1), p.151-158

2003

Volltextzugriff (PDF)

The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis

Multiple sclerosis, 2009-05, Vol.15 (5), p.601-605

2009

Volltextzugriff (PDF)

Are ex vivo neutralising antibodies against IFN-β always detrimental to therapeutic efficacy in multiple sclerosis?

Multiple sclerosis, 2007-06, Vol.13 (5), p.616-621

2007

Volltextzugriff (PDF)

In Vitro Cytokine Responses to Periodontal Pathogens: Generalized Aggressive Periodontitis is Associated with Increased IL-6 Response to Porphyromonas gingivalis

Scandinavian journal of immunology, 2010-06, Vol.71 (6), p.440-446

2010

Volltextzugriff (PDF)

1 – 25 von 570

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(513)
Mit Volltextzugriff
(440)

Publikationsform

Sprache

Englisch
(546)
Dänisch
(24)

Erscheinungsjahr

n.n

Thema

Humans
(377)
Science & Technology
(321)
Life Sciences & Biomedicine
(318)
Biological And Medical Sciences
(225)
Male
(175)
Immunology
(157)
Female
(152)
Medical Sciences
(152)
Adult
(144)
Animals
(113)
Middle Aged
(104)
Fundamental And Applied Biological Sciences. Psychology
(81)
Aged
(60)
Cells, Cultured
(56)
Cytokines
(53)
Fundamental Immunology
(53)
Adolescent
(48)
Pharmacology. Drug Treatments
(48)
Interleukin-1 - Pharmacology
(44)
Immunobiology
(43)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Monitoring patients treated with anti-TNF-α biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies

Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab?

Monitoring patients treated with anti-TNF- biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies

Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease

Prognostic laboratory markers of joint damage in rheumatoid arthritis

Lewis and AB0 blood group-phenotypes in periodontitis, cardiovascular disease, obesity and stroke

Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis

Pre‐existing IgG antibodies cross‐reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

Cytokines, autoantibodies and viral antibodies in premorbid and postdiagnostic sera from patients with rheumatoid arthritis: case–control study nested in a cohort of Norwegian blood donors

Letter: persistence of anti-infliximab antibodies after discontinuation of infliximab in patients with IBD

Is there a need for immunopharmacologic guidance of anti–tumor necrosis factor therapies?

Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease

Single nucleotide polymorphisms in genes encoding toll-like receptors 7, 8 and 9 in Danish patients with systemic lupus erythematosus

Serum concentrations of the interferon-γ-inducible chemokine IP-10/CXCl10 are augmented in both newly diagnosed Type I diabetes mellitus patients and subjects at risk of developing the disease

Genetic polymorphisms of dsRNA ligating pattern recognition receptors TLR3, MDA5, and RIG-I. Association with systemic lupus erythematosus and clinical phenotypes

Neutralizing antibodies hamper IFNβ bioactivity and treatment effect on MRI in patients with MS

Lower limb ischaemia and reperfusion injury in healthy volunteers measured by oxidative and inflammatory biomarkers

Specific and Strain-Independent Effects of Dexamethasone in the Prevention and Treatment of Experimental Autoimmune Encephalomyelitis in Rodents

FRI0031 Naturally occurring antibodies against different IFN-alpha subtypes are observed in some SLE patients, and may impact the IFN gene signature and disease activity

Commentary: antibodies reacting with the infliximab Fab portion – something new? Authors' reply

Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor‐α and interferon‐γ, and has potential in the treatment of arthritis

The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis

Are ex vivo neutralising antibodies against IFN-β always detrimental to therapeutic efficacy in multiple sclerosis?

In Vitro Cytokine Responses to Periodontal Pathogens: Generalized Aggressive Periodontitis is Associated with Increased IL-6 Response to Porphyromonas gingivalis

Suchergebnisse filtern